


Amendments to the Claims


The listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:


- 5 Claim 31 (currently amended): A compound of the formula:



3




4



5

5



or a pharmaceutically acceptable salt thereof.

Claim 32-40: Cancelled.


- 5 Claim 41 (currently amended): A pharmaceutical composition comprising at least one compound of claim 31 in combination with at least one pharmaceutically acceptable carrier.
- Claim 42 (currently amended): The pharmaceutical composition of claim 41
- 10 39, additionally comprising one or more anti-cancer agents selected from the group consisting of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan,
- 15 gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine,
- 20 Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone proplionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone,
- 25 Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine,

6

Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrozole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.


Claim 43 (previously presented): A compound of claim 31 in purified form.

- 5 Claim 44 (previously presented): A compound of the formula:




or a pharmaceutically acceptable salt thereof.

Claim 45 (previously presented): A compound of the formula:



- 10 or a pharmaceutically acceptable salt thereof.


Claim 46 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.


Claim 47 (previously presented): A compound of the formula:

7




or a pharmaceutically acceptable salt thereof.

Claim 48 (previously presented): A compound of the formula:




5 or a pharmaceutically acceptable salt thereof.

Claim 49 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 50 (previously presented): A compound of the formula:




10

or a pharmaceutically acceptable salt thereof.


Claim 51 (previously presented): A compound of the formula:

8




or a pharmaceutically acceptable salt thereof.

Claim 52 (previously presented): A compound of the formula:




5 or a pharmaceutically acceptable salt thereof.

Claim 53 (previously presented): A compound of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 54 (previously presented): A compound of the formula:



10

or a pharmaceutically acceptable salt thereof.

Claim 55-59: Cancelled.

Claim 60 (previously presented): A pharmaceutical composition comprising (i) a compound of claim 44-54 or a pharmaceutically acceptable salt thereof, and (ii) temozolomide.

5 Claim 61-70: Cancelled.

Claim 71 (new claim): A pharmaceutical composition comprising at least one compound of claim 44-54 in combination with at least one pharmaceutically acceptable carrier.

10 Claim 72 (new claim): The pharmaceutical composition of claim 71, additionally comprising one or more anti-cancer agents selected from the group consisting of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, CPT-11, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, 5FU, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa,
15 Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chloromethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine,
20 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone,
25 Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbine, CPT-11,
30 Anastrozole, Letrozole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.